New study could improve early lung cancer detection for Hodgkin lymphoma survivors
A new study has opened in òòò½ÎÑÊÓÆµ which could improve screening and early detection of lung cancer for high-risk Hodgkin lymphoma survivors, following a £1.3 million funding award.
The University of òòò½ÎÑÊÓÆµ project has been awarded the grant through the NHS Cancer Programme Innovation Open Call with support from SBRI Healthcare (Small Business Research Initiative) as part of a new, unique national partnership which could save lives and improve quality of life.
Researchers in òòò½ÎÑÊÓÆµ will implement an innovative lung cancer risk assessment tool and an adapted care pathway for Hodgkin lymphoma survivors, supported by the National Institute for Health and Care Research (NIHR) òòò½ÎÑÊÓÆµ Biomedical Research Centre (BRC).
The new multi-centre study started in June 2025 and will be running for two years within the existing NHS Lung Cancer Screening Programme at 10 Cancer Alliances across England, including Greater òòò½ÎÑÊÓÆµ Cancer Alliance leading the initiative.
Every year, around 2,100 people in the UK are diagnosed with Hodgkin lymphoma, a cancer that develops in the lymphatic system (part of the immune system).
Although it is a highly curable cancer, treatments such as chemotherapy and radiotherapy to the chest and lungs increase the risk of second cancers occurring in later life. This risk increases further for people who smoke.
Survivors of Hodgkin lymphoma are six times more likely to develop lung cancer than the general population.
Study lead Dr Kim Linton, Senior Lecturer at The University of òòò½ÎÑÊÓÆµ and Living With and Beyond Cancer Co-Theme Lead at òòò½ÎÑÊÓÆµ BRC, said: “It is crucial that Hodgkin lymphoma survivors can access screening to detect lung cancer at an early stage, when it is more treatable.â€
Developed in òòò½ÎÑÊÓÆµ, the new UK-wide programme aims to screen 500 Hodgkin lymphoma survivors over two years, which could detect early lung cancer in an estimated 10-12 people.
Joanne Murray, from Didsbury in òòò½ÎÑÊÓÆµ, was diagnosed with Hodgkin lymphoma in 1997 at the age of 29 and received successful treatment at The Christie NHS Foundation Trust.
She took part in the pilot study in 2022 which helped òòò½ÎÑÊÓÆµ researchers design the new national programme. Despite having no symptoms, the study found Joanne had stage 1 lung cancer.
Now 56 and living in North Wales, Joanne said: “I feel exceptionally lucky that this research has saved my life. I had no symptoms of lung cancer and had I not taken part in this study, it might have been too late for me once symptoms had appeared.â€
Through the study, Joanne had a CT scan at The Christie in òòò½ÎÑÊÓÆµ which revealed a ‘fluffy’ and opaque nodule (small lump) on her right lung. Following surgery to remove part of her lung, a biopsy revealed it was stage 1 cancer.
Joanne, who works for North Wales Police, explained: “After my scan, doctors closely monitored me through ‘watch and wait’, with regular check-ups to determine if the nodule grew or if I developed symptoms. In November 2023, after I had moved to Wales, a follow-up scan at my local hospital showed that the nodule had grown by 1mm. After discussing my treatment options, I decided to have surgery to remove part of my right lung.â€
Joanne had the surgery in January 2024 at Liverpool Heart and Chest Hospital. She said: “I was absolutely terrified of having the surgery, but it was fine, and all the staff were fantastic. I had video-assisted thoracoscopic surgery [a form of keyhole surgery] which was less invasive, and I was back home in two days to recover.
“When I found out from the biopsy that it had been stage 1 cancer, I was in complete shock. I’m a positive person and thought I had just been overthinking it. I am so thankful for this vital research and the team at The Christie.â€
Now 18 months later, Joanne has had two clear scans, with the next one due in early 2026.
On taking part in research, Joanne said: “When I read the letter asking me if I wanted to be part of research I thought, ‘there’s nothing wrong with me, but I’ll do it.’ You never know what’s around the corner.
“Without doubt, I would urge other cancer survivors to take part in screening. It might take 10 or 15 minutes out of your day, but it could save your life.â€
Hodgkin lymphoma can develop at any age, but it mostly affects people between 20 and 40 years of age and those over 75. The most common symptom is a painless swelling in a lymph node, usually in the neck, armpit or groin.
Second cancers, such as lung cancer or breast cancer, can develop more than 10 years after treatment for Hodgkin lymphoma. Survivors can help to reduce their risk of a second cancer by adopting a healthy lifestyle through not smoking, maintaining a healthy weight with a balanced diet, and getting regular exercise.
Dr Linton, who is also an Honorary Consultant in Medical Oncology at The Christie NHS Foundation Trust, said: “Most Hodgkin lymphoma survivors do not meet current lung cancer screening criteria, so we hope the success of this study will support an application for routine adoption across England and Wales.
“In òòò½ÎÑÊÓÆµ, we have been working on a lung cancer screening programme for Hodgkin lymphoma survivors for many years, including a pilot screening study at The Christie where we detected 3 lung cancers in 102 people who had showed no symptoms.
“This research helped us to design the national programme and confirmed that our proposed study meets the needs of this high-risk patient group. This work also builds on òòò½ÎÑÊÓÆµâ€™s previous track record of successfully implementing breast cancer screening for Hodgkin lymphoma survivors within the national breast cancer screening programme.â€
It is crucial that Hodgkin lymphoma survivors can access screening to detect lung cancer at an early stage, when it is more treatable
The new study will be open to Hodgkin lymphoma survivors aged between 45 and 74 who smoke or have previously smoked.
It will have an embedded programme to identify and tackle health inequalities, including people where their risk of lung cancer is highest, such as those with lower socioeconomic status, men and older people.
It will help address barriers to screening participation, such as fear of cancer diagnosis, low perceived risk of cancer and issues of cost, travel and time off work.
Screening will take place at convenient community-based settings to encourage participation, including in mobile clinics at supermarket car parks.
Researchers will actively promote screening participation for people with the highest smoking prevalence.
Participants will be offered health education and stop smoking advice to encourage supported self-management to prevent lung cancer, cardiovascular disease and other significant illnesses, which could lead to improved survivorship and reduced healthcare costs.
The òòò½ÎÑÊÓÆµ-based project is part of the NIHR òòò½ÎÑÊÓÆµ BRC’s , which aims to transform the detection of cancer recurrence and second cancers to improve quality of life and treatment outcomes for survivors.
Researchers will also be collaborating with the NIHR òòò½ÎÑÊÓÆµ BRC’s , which aims to reduce cancer burden across society through implementing prevention and early detection strategies.
The project will be supported by the NIHR Oncology Translational Research Collaboration, Lymphoma Action charity and patient partners.
Health Innovation òòò½ÎÑÊÓÆµ will work with Greater òòò½ÎÑÊÓÆµ Cancer Alliance to support local adoption and run patient focus groups to understand barriers to engagement and develop solutions to improve uptake.
- images: Dr Kim Linton and Joanne and Rob